Evidence map›Paper›PMID 28589310›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2017

Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.

J Matt McCrary, David Goldstein, Frances Boyle, Keith Cox, Peter Grimison, Matthew C Kiernan, Arun V Krishnan, Craig R Lewis, Kate Webber, Sally Baron-Hay and 3 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. BeyondFrontiers in pain research (Lausanne, Switzerland) · 2025
    Pooled it
  3. Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Pooled it
  4. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  5. Effects of an exercise program on chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer individuals receiving taxanes: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Trial
  13. Feasibility of clinical implementation and acceptability of patient-reported screening for chemotherapy-induced peripheral neuropathy (CIPN).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

J Matt McCraryPrince of Wales Clinical School, UNSW Medicine, The University of New South Wales, Randwick, NSW, 2031, Australia.
David GoldsteinPrince of Wales Clinical School, UNSW Medicine, The University of New South Wales, Randwick, NSW, 2031, Australia.
Frances BoyleSydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.
Keith CoxSydney Nursing School, The University of Sydney, Sydney, NSW, 2006, Australia.
Peter GrimisonSydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.
Matthew C KiernanBrain & Mind Centre, The University of Sydney, 94-100 Mallett Street, Camperdown, Sydney, NSW, 2050, Australia.
Arun V KrishnanPrince of Wales Clinical School, UNSW Medicine, The University of New South Wales, Randwick, NSW, 2031, Australia.
Craig R LewisPrince of Wales Clinical School, UNSW Medicine, The University of New South Wales, Randwick, NSW, 2031, Australia.
Kate WebberPrince of Wales Clinical School, UNSW Medicine, The University of New South Wales, Randwick, NSW, 2031, Australia.
Sally Baron-HayDepartment of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia.
Lisa HorvathSydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.
Susanna B ParkPrince of Wales Clinical School, UNSW Medicine, The University of New South Wales, Randwick, NSW, 2031, Australia. Susanna.park@sydney.edu.au.
IN FOCUS Delphi working party

Funding

Cancer Institute NSW 14/TPG/1-05National Health and Medical Research Council 1037746National Health and Medical Research Council 1080521
6 · The paper itself

Abstract

background/purposeChemotherapy-induced peripheral neuropathy (CIPN) is a prominent side effect of the treatment of cancer. Despite this frequent complication, there has been no comprehensive review and quality appraisal of CIPN assessments. The purpose of this study is to provide a definitive quality appraisal of CIPN assessment strategies for clinical use.

methodsRelevant studies were identified through database searches of Medline, Embase, CINAHL, and Cochrane. CIPN assessment strategies from included articles were extracted and initially rated by an oncologist and neurophysiologist according to criteria related to assessment depth, comprehensiveness, appropriateness, and reliability. The six highest scoring assessment strategies were the focus of a two-round Delphi survey of a working party of 32 physicians, nurses, and consumers to achieve consensus on the highest rated assessments for each criterion.

resultsThe database search yielded 117 distinct CIPN assessments that were extracted from 2373 articles. Three patient-reported outcome surveys and three clinician-based assessments were included in the Delphi survey. No consensus was generated regarding the best overall CIPN assessment, although good (≥70%) consensus was achieved regarding the best assessment within each criterion. The Participant Neurotoxicity Questionnaire (PNQ) was rated the highest overall and patient-reported outcome (PRO) assessment, while the Total Neuropathy Score clinical version (TNSc) was the highest rated clinician-based assessment.

conclusionsA diverse range of CIPN assessments currently exists. While several assessments assess CIPN symptoms with adequate comprehensiveness, depth, language, and feasibility, the consensus 'gold standard' clinical assessment remains to be established.

Indexed as

Antineoplastic AgentsFemaleHumansNeoplasmsNeurotoxicity SyndromesPeripheral Nervous System DiseasesReproducibility of ResultsSurveys and QuestionnairesAntineoplastic AgentsChemotherapyNeuropathyPeripheral nervous system diseasesSymptom assessment

Identifiers

PMID28589310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.